Klara Norra Kyrkogata 26
Stockholm 111 22
Sweden
46 86 79 72 10
https://www.egetis.com
Settore/i:
Settore:
Impiegati a tempo pieno: 28
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Nicklas Westerholm | Chief Executive Officer | 4,8M | N/D | 1976 |
Mr. Torsten Almén | Founder | N/D | N/D | N/D |
Dr. Ingemar Lundström Ph.D. | Founder | N/D | N/D | 1943 |
Dr. Louis Joseph Ignarro Ph.D. | Founder | N/D | N/D | 1942 |
Associate Prof. Heidi Brurok | Founder | N/D | N/D | N/D |
Dr. Rob Towart | Founder | N/D | N/D | N/D |
Dr. Yilmaz Mahshid Ph.D. | Chief Financial Officer | N/D | N/D | 1979 |
Dr. Katayoun Welin-Berger Ph.D. | Vice President of Operations | N/D | N/D | 1968 |
Dr. Jacques Näsström M.B.A., MBA, Ph.D. | Chief Scientific Officer | 655k | N/D | 1959 |
Dr. Karl Hard Ph.D. | Head of IR & Business Development | N/D | N/D | 1962 |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
L'ISS Governance QualityScore di Egetis Therapeutics AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.